Melanocortin receptor activation.
Engaging melanocortin receptors, relevant to pigmentation, sexual arousal, and inflammation.
The melanocortin system consists of five G-protein-coupled receptors, MC1R through MC5R, and their natural ligands derived from proopiomelanocortin, including alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone. Each receptor subtype has a different distribution and a different job, which is why compounds acting on this family produce such varied effects depending on which receptors they touch. MC1R sits on epidermal melanocytes. Activating it raises cyclic AMP and shifts melanin synthesis toward eumelanin, the darker and more photoprotective pigment, independent of ultraviolet exposure. MC3R and MC4R are concentrated in the hypothalamus and limbic regions, where they participate in circuits governing appetite, energy balance, and sexual motivation. MC4R activation in particular is the accepted basis for centrally acting effects on arousal, which operate on motivation pathways rather than on vascular or genital tissue. MC5R is associated with exocrine gland function. Several melanocortin ligands also have anti-inflammatory activity, and this branch is pursued separately. Compounds in this group differ mainly by selectivity, and this is the distinction that determines both intended effect and side effect. A highly MC1R-selective analog is used to increase photoprotective pigmentation and is designed to avoid central receptors. Non-selective agonists bind across most of the family, which is why they produce pigmentation, appetite change, nausea, and arousal effects together rather than separately. A related tripeptide corresponding to the carboxy-terminal fragment of alpha-melanocyte-stimulating hormone retains anti-inflammatory activity but appears to work largely without classical melanocortin receptor engagement, entering cells through a peptide transporter instead. All of these analogs incorporate amino-acid substitutions that resist enzymatic breakdown, since the native hormones are short-lived. Clinical standing varies sharply within the group. Two members are approved medicines in at least some jurisdictions for narrowly defined indications, meaning their receptor mechanisms have been demonstrated in humans. Others in the group have never been approved anywhere and are sold as unregulated research chemicals. Non-selective melanocortin agonism in particular carries documented concerns including nausea, blood pressure effects, and changes to moles and pigmented lesions, and using pigmentation-inducing compounds without dermatological monitoring is widely cautioned against. Receptor pharmacology being well understood does not make an unapproved compound safe. The selectivity point is worth restating, because it is the single most useful thing to know about this family: the difference between a compound that touches one melanocortin receptor and one that touches all five is the difference between a narrow effect and a diffuse one.
Peptides acting through this pathway.
FAQ.
What does melanocortin receptor activation do?
The melanocortin system consists of five G-protein-coupled receptors, MC1R through MC5R, and their natural ligands derived from proopiomelanocortin, including alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone. Each receptor subtype has a different distribution and a different job, which is why compounds acting on this family produce such varied effects depending on which receptors they touch. MC1R sits on epidermal melanocytes. Activating it raises cyclic AMP and shifts melanin synthesis toward eumelanin, the darker and more photoprotective pigment, independent of ultraviolet exposure. MC3R and MC4R are concentrated in the hypothalamus and limbic regions, where they participate in circuits governing appetite, energy balance, and sexual motivation. MC4R activation in particular is the accepted basis for centrally acting effects on arousal, which operate on motivation pathways rather than on vascular or genital tissue. MC5R is associated with exocrine gland function. Several melanocortin ligands also have anti-inflammatory activity, and this branch is pursued separately. Compounds in this group differ mainly by selectivity, and this is the distinction that determines both intended effect and side effect. A highly MC1R-selective analog is used to increase photoprotective pigmentation and is designed to avoid central receptors. Non-selective agonists bind across most of the family, which is why they produce pigmentation, appetite change, nausea, and arousal effects together rather than separately. A related tripeptide corresponding to the carboxy-terminal fragment of alpha-melanocyte-stimulating hormone retains anti-inflammatory activity but appears to work largely without classical melanocortin receptor engagement, entering cells through a peptide transporter instead. All of these analogs incorporate amino-acid substitutions that resist enzymatic breakdown, since the native hormones are short-lived. Clinical standing varies sharply within the group. Two members are approved medicines in at least some jurisdictions for narrowly defined indications, meaning their receptor mechanisms have been demonstrated in humans. Others in the group have never been approved anywhere and are sold as unregulated research chemicals. Non-selective melanocortin agonism in particular carries documented concerns including nausea, blood pressure effects, and changes to moles and pigmented lesions, and using pigmentation-inducing compounds without dermatological monitoring is widely cautioned against. Receptor pharmacology being well understood does not make an unapproved compound safe. The selectivity point is worth restating, because it is the single most useful thing to know about this family: the difference between a compound that touches one melanocortin receptor and one that touches all five is the difference between a narrow effect and a diffuse one.
Which peptides act through melanocortin receptor activation?
Melanotan II, PT-141, Afamelanotide, KPV. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.